Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358564 · ClinicalTrials.gov registry record · NA
Gut Permeability, Sensitivity and Symptomatology
A NA study of Irritable Bowel Syndrome and Visceral Hypersensitivity, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT02358564: Completed NA study of Irritable Bowel Syndrome and Visceral Hypersensitivity, sponsored by Mayo Clinic.
NCT02358564 is a NA study of Irritable Bowel Syndrome and Visceral Hypersensitivity that has completed, run by Mayo Clinic. The registered enrollment target is 39 participants, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02358564, a NA study of Irritable Bowel Syndrome and Visceral Hypersensitivity, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
To better understand the relationship between gut barrier function and the symptomatology and pathophysiology of irritable bowel syndrome (IBS).
Conditions Studied
Interventions
- PROCEDURE Gastrointestinal Permeability Test
- PROCEDURE Upper Endoscopy
- PROCEDURE Rectal Barostat and Infusion of Fats
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-02 |
| Est. Completion | 2021-03-11 |
| Phase | NA |
What the finished NCT02358564 record still lists
NCT02358564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Gastrointestinal Permeability Test is the first listed.
NCT02358564 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02358564 about?
NCT02358564 is a clinical study titled "Gut Permeability, Sensitivity and Symptomatology". To better understand the relationship between gut barrier function and the symptomatology and pathophysiology of irritable bowel syndrome (IBS).
What is the current status of trial NCT02358564?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2015-02. Estimated completion is 2021-03-11.
What conditions does trial NCT02358564 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome, Visceral Hypersensitivity.
What interventions are being tested in trial NCT02358564?
The interventions under investigation include: Gastrointestinal Permeability Test (PROCEDURE), Upper Endoscopy (PROCEDURE), Rectal Barostat and Infusion of Fats (PROCEDURE).
Who is sponsoring clinical trial NCT02358564?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02358564 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02358564's enrollment target sits among peer trials
39 39th of 47 higher than 8 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
RECRUITING · NA
-
GI Alpha-Gal Study
RECRUITING · NA
-
Visible Abdominal Distension
RECRUITING · NA
-
IBS Skin Patch Test Food Allergy Study
RECRUITING · NA
-
Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome
RECRUITING · NA
-
Well-being in IBS: Strengths and Happiness (WISH) 2.0
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia